Can a statin tame a cancer protein? early trial seeks answers
NCT ID NCT03560882
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or treatment. The main goal is to see if the drug lowers the abnormal protein, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Cancer Center - CRC
Fairway, Kansas, 66205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Could muscle loss predict blood cancer outcomes?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?